Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $3.01 Billion |
|---|---|
| Enterprise Value | $3.33 Billion |
| Annual dividend | $0.64 |
| Earnings per Share | $1.68 |
| Beta | -0.06 |
| Outstanding Shares | 118,000,000 |
| P/E Ratio | 9.66 |
|---|---|
| PEG | 4.27 |
| Price to Sales | 1.99 |
| Price to Book Ratio | -10.92 |
| Enterprise Value to Revenue | 2.42 |
| Enterprise Value to EBIT | 5.84 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -2.59 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...
In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.
Stockcircle shows 2 open-market insider purchases and 3 open-market insider sales for Indivior Plc in the last six months from SEC Form 4 reports by executives, directors, and other insiders.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.